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Introduction 
Health services in Africa have a very severe shortage of doctors and nurses with less than 10 
doctors per 100,000 population in several countries 1 and access to health services is 
difficult for many patients because of high transport costs 2. Despite these constraints, and 
the limited experience in delivering chronic care in Africa, antiretroviral therapy (ART) has 
been scaled up rapidly and about 8 million people are now on treatment 3. In most 
countries, the HIV services are delivered as stand-alone vertical programmes 4.  
 
Non-communicable diseases (NCDs) also require chronic care and their burden is rising 
rapidly in Africa 5, 6. The demands for delivering chronic care services will increase 
substantially 7; but African health systems are geared towards the control of acute 
infections 8. Research on how to organise and deliver chronic care services in Africa will be 
essential in order to target the scarce resources efficiently 9. Such research has to be 
integrated into health systems because its central aim is usually to estimate the 
effectiveness of models of health service delivery under near normal conditions in order 
that the findings can be generalised immediately. This is in contrast to many efficacy trials 
(e.g. of drugs and vaccines) which are usually implemented under parallel systems.  We 
have previously examined the use of cluster-randomisation for a vaccine efficacy trial 10 and 
examined the operational and ethical issues of integrating research into routine health 
service delivery 11. Here we focus on the study design challenges, with a particular focus on 
whether such trials should be cluster or individually randomised.  
 
Methods 
We examine the issues using our experiences from two trials. The REMSTART trial was 
designed to evaluate the effectiveness of a complex health service intervention in reducing 
mortality among HIV-infected patients who presented with very low CD4 count to 6 
government clinics in Dar es Salaam, Tanzania and Lusaka, Zambia (ISCRTN 20410413). 
Enrolment began in February 2012 and ended in September 2013. Follow-up is scheduled to 
end in September 2014. Initially, only patients with CD4 count less than 100 /μl were eligible 
for enrolment but the criteria were changed during the course of the trial to enrol any 
patient presenting with less than 200 CD4 cells /μl because of slow recruitment and because 
of the increasing recognition such patients had a high risk of death. Just prior to that, the 
criteria for initiating antiretroviral therapy changed from initiation at CD4 count<200 / μl to 
initiation at CD4 count<350 /μl. The World Health Organisation has recently recommended 
that antiretroviral therapy should now be initiated at CD4 count<500 cells /μl 12. The change 
in recruitment criteria of the REMSTART trial was implemented in September 2012 in 
Zambia and in December 2012 in Tanzania.  
 
The REMSTART trial intervention comprised i) rapid initiation of antiretroviral therapy, ii) 
screening for cryptococcal meningitis using a novel antigen test, iii) weekly home visits for 4 
weeks by trained lay-workers iv) re-screening for tuberculosis using the Xpert®MTB/RIF 
assay (Cepheid, Sunnyvale, USA) at about 6 weeks after initiation of ART. Patients were 
randomised to either this intervention strategy or to standard clinic-based HIV care 
including ART. All participants were offered screening for tuberculosis at baseline using the 
Xpert®MTB/RIF assay irrespective of whether they had any symptoms or not. Participants 
were followed up for 12 months after enrolment. The primary endpoint was all-cause 
mortality.  
 
The Jinja trial compared a home-based with a facility-based HIV care strategy in Jinja, 
Uganda, a predominantly rural setting 13. The home-based strategy involved trained lay-
workers visiting the patient at home on a monthly basis. ART was provided by The AIDS 
Support Organisation (TASO), a large non-governmental organisation. The vast majority of 
HIV-infected patients in the Jinja district accessed ART services at TASO. There was little 
provision for ART in government facilities at the time (the TASO clinic was based within the 
grounds of the Jinja District Hospital). Enrolment into the trial ended in December 2006, and 
follow-up continued until January 2009.   
 
In both trials, lay-workers received a small salary and were supervised by clinicians and 
nurses based at the clinics. They received class-room training at the beginning (4 weeks in 
the Jinja trial, 2 weeks in REMSTART) and on-the-job training subsequently. In the home, 
they delivered drugs, provided adherence support, and monitored the participants for 
adverse events using a checklist. They referred patients if indicated and phoned a clinician 
based at the clinic when they were uncertain about referral. In the Jinja trial, lay-workers 
travelled on motorbikes while in REMSTART they travelled mostly by foot and public 
transport.  
 
How should health service delivery trials be randomised? Because health care is delivered 
to groups (e.g. catchment populations of health centres), such trials are normally cluster-
randomised with all participants in a defined cluster receiving the same mode of care - 
either the intervention or the control strategy 14. Typically 6 or more clusters are 
randomised to each arm 15. This design mimics the real life situation – it is how health care 
would normally be delivered.  
 
One major challenge in health service trials is that patients or the health care personnel 
might have strong views on how health care should be delivered. For example, clinic-based 
care can incur substantial transport costs and home-based care involves disclosure of HIV 
status and stigma. In Jinja, Uganda, a single clinic visit cost the equivalent of an average 13% 
of man’s and 20% of a woman’s monthly wage and took a day of the patient’s time 13; and 
19 people in the home-based care arm versus only 3 in the facility arm refused to join for 
fear of increased stigma . We considered that individual randomisation would be a major 
challenge in Jinja but the concept of neighbourhoods having the same mode of care might 
be acceptable. Because of similar concerns over consent, trials of breast-feeding practices 
have not been randomised and instead the breastfeeding groups have been defined by the 
choices made by the women 16. Although, there might have been no alternative, the 
evidence from such studies is weaker than that from randomised trials.  
 
One reason for randomising by clusters is to avoid interaction between people receiving 
different modes of care (known as contamination). For example, adherence messages 
delivered to people on one arm could be passed to people in the other arm, thus diluting 
the efficacy of the intervention. In Jinja, the TASO clinic provided the vast majority of 
antiretroviral therapy within a 100km radius for several years and cluster-randomisation 
ensured separation in the community of people receiving different models of care. 
However, HIV care is now available widely in Africa and achieving that separation between 
people on antiretroviral therapy is no longer possible. We decided to randomise the 
REMSTART trial individually in the belief that contamination was not a major issue because 
the intervention had only one behavioural component – adherence support delivered by a 
trained lay-worker - and contamination between participants might not influence the 
effects of this. Also the chances of neighbours being in the trial in different trials arms was 
small (we planned to enrol about 2500 participants from a total catchment population of 
well over 150,000 urban adults) and the chances of contamination at clinic visits would be 
minimised given the high degree of activities at each clinic.   
 
Statistical power considerations. Complex interventions involve multiple components, 
making sample size difficult to estimate. A further complication is that trial conditions can 
change with changes in management guidelines or practices. Thus, it is essential that 
assumptions underlying the trial are reviewed periodically and trial size is adjusted where 
this is indicated.  
 
Increasing the trial size in an individually randomised trial is usually relatively 
straightforward. In cluster-randomised trials, the number of clusters is usually the major 
determinant of statistical power, and adding new clusters during the course of a trial is 
often impractical. This is a significant drawback with cluster-randomisation. Sample size 
calculations for cluster-randomised trials also require an estimate of the variability between 
clusters (e.g. the coefficient of variation), which is rarely known in advance.  
 
Table 1 shows the sample size calculations for the REMSTART trial as designed and if instead 
this were cluster-randomised assuming coefficient of variation to be 0.1 or 0.2 15. Cluster-
randomisation requires large increases in sample size to achieve the same level of power.  
 
 
Table 1. Total number of participants needed in both groups combined in a two-arm 
randomised trial to detect a 40% reduction in mortality at 90% power and 5% significance level 
 
Mortality (percent per year) If trial is 
individually 
randomised 
If trial is cluster-randomised 
Control arm Intervention arm 12 clusters 24 clusters 
   k=0.2 k=0.1 k=0.2 k=0.1 
8 4.8 2624 11005 3833 4238 3116 
10 6.0 2100 8804 3067 3391 2493 
12 7.2 1750 7337 2556 2825 2077 
14 8.4 1500 6289 2191 2422 1780 
       
       
Note, k is the coefficient of variation.  
 
 
Blinding in health service trials. Blinding is rarely possible in trials of health care delivery, 
whether they are randomised individually or by clusters and this can be a major source of 
bias. It is vital that both researchers and health care staff assume equipoise; not doing so 
will affect the implementation of the intervention and the measurement of outcomes.  
It is important that health care staff are informed about the wider aspects of research, 
including its need and uses and that they feel that they have ownership of the research 
programme. It is essential that health care staff understand the concepts of bias and the 
need for equipoise. Providing training in research methods alone is not enough in such 
settings.  
 
Control for confounding. In large, individually-randomised trials, factors that are predictive 
of the outcome tend to be equally distributed between the trial arms. In cluster-randomised 
trials, the number of clusters is usually limited and imbalance between two arms is 
common. For example, in the Jinja trial, 22 clusters were randomised to each strategy – 44 
clusters in total 13. By chance the number enrolled differed substantially between the two 
arms (859 in the home-based care arm compared to 594 for facility) and median CD4 count 
was significantly lower in the home-based arm. The difficulty in health service trials is that 
some confounders may be unknown and key known confounders such as socio-
demographic variables, access to the clinic, income and ability to afford transport are all 
difficult to measure; therefore imbalances between arms are difficult to assess and difficult 
to adjust in analyses.   
 
Data collection 
Data collected by health care staff might be of poorer quality than those collected by 
researchers as their first priority is to attend to the clinical needs of the patient. Despite this, 
it is critical that there is zero tolerance of incomplete or inaccurate data. In the REMSTART 
trial, only essential  data in simplified form were collected by clinicians and independent 
monitoring of the data was usually done within about 30 minutes of the patient emerging 
from the consultation and while the patient is still in clinic so that queries can be resolved.  
 
Data collection can be especially problematic in cluster-randomised trials as extensive data 
need to be collected to adjust for the possibility of confounding. The risk of confounding is 
negligible in large-scale individually-randomised trials and so much greater focus can be 
placed on the measurement of essential outcome data.  
 
Consistency in the delivery of standard care and in implementation of the intervention 
strategy. Health care delivery trials require a comparison between standard care and the 
intervention. However, standard care often varies between Ministry of Health guidelines 
and practices within clinics. Bringing change and implementing a new strategy (i.e. the 
intervention arm) in busy, over-stretched facilities brings further variation. In an individually 
randomised trial, standardisation is easier to achieve because fewer clinics are involved than 
in a cluster-randomised trial. In a cluster-randomised trial, resources are required in each 
clinic in order to standardise delivery and to monitor to what extent delivery is in 
accordance to protocol.  
 
The danger in individually randomised trials is that if health care workers can see 
components of an intervention working well, they might be tempted to introduce it for 
control subjects; likewise poorly functioning components of an intervention might be 
dropped. In cluster-randomisation, there is much less interaction between health care staff 
in different facilities, such that different models of care can co-exist for longer.  
 
In the REMSTART trial, rapid initiation of ART was perceived to be working well in the 
intervention arm and at the same time there was pressure to increase the number on ART in 
order to meet targets; consequently, the practices within the clinics changed in both 
countries to initiate ART rapidly in both arms of the trial. Had the trial been cluster-
randomised, this change in practice may have taken longer.  
 
 
Conclusions 
Trials to address health service delivery questions provide valuable information to guide 
health care delivery but pose major challenges for health services and researchers. Blinding 
is rarely possible. Cluster-randomised trials mimic more closely the real life setting of how 
care is normally delivered, but power is reduced and control for confounding and a 
standardised delivery at the various clinics are more difficult to achieve. Interaction 
between trial participants and non-trial participants receiving different modes of care is 
unavoidable for chronic care services which are available in multiple settings. Control for 
confounding is challenging in cluster-randomised trials. Accurate data on potential 
confounders have to be collected but extensive data collection is impractical in busy clinic 
settings. In any case, the confounders in health services research are not well understood or 
difficult to measure. Partnerships between researchers, health care workers, public health 
staff and patient groups are essential in health systems research. 
 
 
REFERENCES 
 
1. World Health Organization. World Health Report 2006 - working together for 
health. Geneva: World Health Organization, 2006. 
2. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for 
linkage to antiretroviral therapy care: a systematic review. AIDS 2012; 26(16): 2059-67. 
3. World Health Organization. Global update on HIV treatment 2013: results, 
impact and opportunities. Geneva: World Health Organization, 2013. 
4. Munderi P, Grosskurth H, Droti B, Ross DA. What are the essential components of 
HIV treatment and care services in low and middle-income countries: an overview by 
settings and levels of the health system. AIDS 2012; 26(Supplement 2): S97-S103. 
5. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of 
disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 
2012; 380(9859): 2224-60. 
6. World Health Organization. Global health risks: mortality and burden of disease 
attributable to selected major risks. Geneva: World Health Organization, 2009. 
7. Alleyne G, Binagwaho A, Haines A, et al. Embedding non-communicable diseases 
in the post-2015 development agenda. Lancet 2013; 381(9866): 566-74. 
8. Atun R, Jaffar S, Nishtar S, et al. Improving responsiveness of health systems to 
non-communicable diseases. Lancet 2013; 381(9867): 690-7. 
9. Ebrahim S, Pearce N, Smeeth L, Casas JP, Jaffar S, Piot P. Tackling non-
communicable diseases in low- and middle-income countries: is the evidence from high-
income countries all we need? PLoS Med 2013; 10(1): e1001377. 
10. Jaffar S, Leach A, Hall AJ, et al. Preparation for a pneumococcal vaccine trial in 
The Gambia: individual or community randomisation? Vaccine 1999; 18(7-8): 633-40. 
11. Jaffar S, Amuron B, Birungi J, et al. Integrating research into routine service 
delivery in an antiretroviral treatment programme: lessons learnt from a cluster 
randomized trial comparing strategies of HIV care in Jinja, Uganda. Tropical medicine & 
international health : TM & IH 2008; 13(6): 795-800. 
12. World Health Organisation. Consolidated guidelines on the use of antiretroviral 
drugs for treating and preventing HIV infection – recommendations for a public health 
approach. . Geneva, Switzerland., 2013. 
13. Jaffar S, Amuron B, Foster S, et al. Rates of virologic failure in patients treated in a 
home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-
randomised equivalence trial. Lancet 2009; 374(9707): 2080-9. 
14. Hayes RJ, Moulton LH. Cluster Randomised Trials. London: Chapman & Hall; 
2009. 
15. Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. 
International Journal of Epidemiology 2009; 28(2): 319-26. 
16. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 
infection during exclusive breastfeeding in the first 6 months of life: an intervention 
cohort study. Lancet 2007; 369(9567): 1107-16. 
 
 
